Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Up 8 Percent on Patent News

NEW YORK, Feb. 3 (GenomeWeb News) - Shares in Accelr8 were up 7.95 percent, or $.21, at $2.85 in late-afternoon trading after the company said it won a US patent for its OptiChem surface chemistry.

 

The stock shot up to $3.35 in early-morning trade before settling down to $2.85 in unusually heavy volume.

 

The patent, No. 6,844,028, covers a new coating that "makes it possible to selectively capture, target and analyze individual bacteria. ... "

 

OptiChem is a component of Accelr8 's new BACcelr8r diagnostic system that, "when fully developed, has the potential to replace bacterial culturing by producing test results in a matter of hours," the company said. Results from traditional culturing "typically require several days," Accelr8 said.

Accelr8 currently sells OptiChem-coated slides for research applications, and is developing custom coating formulations for industrial clients.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.